Etrasimod, a next-generation oral selective sphingosine-1-phosphate (S1P) receptor modulator, has emerged as a promising treatment for immune-mediated inflammatory diseases (IMIDs), most notably moderate-to-severe ulcerative colitis (UC). Acting primarily on S1PR1, S1PR4, and S1PR5, etrasimod effectively reduces gastrointestinal inflammation by retaining lymphocytes in lymphoid tissues, thereby minimising systemic immunosuppression and associated risks. Etrasimod provides better safety, a favorable pharmacokinetic profile, and a short washout period when compared to first-generation modulators, improving patient adherence and efficacy. Its therapeutic potential has been highlighted by clinical trials, such as the ELEVATE UC 12 and ELEVATE UC 52 studies, which showed notable improvements in clinical remission and mucosal healing when compared to placebo. With a tolerable safety profile and convenience of once-daily oral dosing, etrasimod stands out as an important advancement in the management of UC and holds further potential in other IMIDs, representing a step forward in targeted, patient-friendly immune modulation.